Studies of hypoxemic/reoxygenation injury: Without aortic clamping IV. Role of the iron-catalyzed pathway: deferoxamine by Morita, Kiyozo et al.
STUDIES OF HYPOXEMIC/ 
REOXYGENATION INJURY: 
WITHOUT AORTIC 
CLAMPING 
IV.  Ro le  o f  the  i ron -  
cata lyzed  pathway:  
de feroxamine  
This study tests the hypothesis that an iron chelator, deferoxamine, can reduce 
oxygen-mediated myocardial injury and avoid myocardial dysfunction after 
cardiopulmonary bypass by its action on the iron-catalyzed Haber-Weiss 
pathway. Twenty-one immature 2- to 3-week-old piglets were placed on 
cardiopulmonary b pass for 120 minutes, and five piglets served as biochem- 
ical controls without cardiopulmonary b pass. Five piglets underwent cardio- 
pulmonary bypass without hypoxemia (cardiopulmonary bypass control). 
Sixteen others became hypoxemic while undergoing cardiopulmonary b pass 
for 60 minutes by lowering oxygen tension to about 25 mm Hg, followed by 
reoxygenation at oxygen tension about 400 mm Hg for 60 minutes. Oxygen 
delivery was maintained uring hypoxemia by increasing cardiopulmonary 
bypass flow and hematocrit level. In seven piglets deferoxamine (50 mg/kg total 
dose) was given both intravenously just before reoxygenation a d by a bolus 
injection (5 mg/kg) into the cardiopulmonary b pass circuit; nine others were 
not treated (no therapy). Myocardial function after cardiopulmonary b pass 
was evaluated from end-systolic elastance (conductance atheter) and Starling 
curve analysis. Myocardial conjugated iene production and creatine kinase 
leakage were assessed as biochemical markers of injury, and antioxidant 
reserve capacity was determined by measuring malondialdehyde in postcar- 
diopulmonary bypass myocardium incubated in the oxidant, t-butylhydroper- 
oxide. Cardiopulmonary bypass without hypoxemia caused no oxidant or 
functional damage. Conversely, reoxygenation ( o therapy) raised myocardial 
conjugated iene levels and creatine kinase production (conjugated iene: 
3.5 _+ 0.7 absorbance 233 nm/min/100 g, creatine kinase: 8.5 - 1.5 U/min/ 
100 g; p < 0.05 versus cardiopulmonary b pass control), reduced antioxidant 
reserve capacity (malondialdehyde: 1115 - 60 nmol/g protein at 4 mmol/L 
t-butylhydroperoxide; p < 0.05 versus control), and produced severe post- 
bypass dysfunction (end-systolic elastance recovered only 39% _ 7%, p < 0.05 
versus cardiopulmonary b pass control). Deferoxamine avoided conjugated 
diene production and creatine kinase release and retained normal antioxidant 
reserve, and functional recovery was complete (95% - 11%,p < 0.05 versus no 
treatment). These findings how that iron-catalyzed oxidants may contribute to 
a reoxygenation injury and imply that deferoxamine may be used to surgical 
advantage. (J THORAC CARDIOVASC SURG 1995;110:1190-9) 
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W e have speculated that abrupt reoxygenation on cardiopulmonary bypass (CPB) causes an un- 
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may add to subsequent intraoperative ischemic 
damage, resulting in postbypass myocardial dysfunc- 
tion. 1 This concept of "iatrogenic reoxygenation 
injury on CPB" is supported by recent clinical 
observations from patients with cyanosis placed on 
CPB 2, 3 and from infants with hypoxemia placed on 
extracorporeal membrane oxygenation. 4 Our former 
studies 5 indicate that oxygen free radicals are in- 
Copyright © 1995 by Mosby-Year Book, Inc. 
0022-5223/95 $ .00 + 0 12/0/66315 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 4, Part 2 
Morita et al. 1 1 9 1 
volved in the pathogenesis of reoxygenation i jury 
of hypoxemic immature hearts and that damage is 
reduced by catalase (a scavenger for hydrogen perox- 
ide) and N-(2-mercaptopropionyl)-glycine, a scavenger 
for hydroxyl radical ('OH) and by the I=arginine ana- 
log that limits cytotoxic products of L-arginine-.NO- 
pathway. 5 
Iron may play a central role in oxygen radical 
generation and the subsequent chain reaction of 
lipid peroxidation, because ferric iron (Fe 3+) cata- 
lyzes the Haber-Weiss reaction, whereby 02-  and 
H202 produce .OH 6 that causes lipid peroxida- 
tion.7, 8 Another potential deleterious role of iron is 
to catalyze the propagation of lipid peroxidation 
after its initiation by "OH. 6 
Deferoxamine, a chelating agent with a high 
affinity for ferric iron (Fe3+), has been found to be 
cardioprotective in various experimental models of 
ischemia/reperfusion 9-13and has been used clinically 
to treat iron and aluminum overload. 14 This study 
tests the hypothesis that deferoxamine will limit 
production of iron-mediated oxidants and reduce 
reoxygenation injury of the hypoxemic immature 
heart. 
Mater ia l  and  methods  
P reparat ion .  Twenty-six immature, 2- to 3-week-old 
Yorkshire-Duroc piglets (3 to 5 kg), were premedicated 
with 0.5 mg/kg diazepam intramuscularly, anesthetized 
with 30 mg/kg pentobarbital intraperitoneally followed by 
5 mg/kg intravenously each hour, and the lungs ventilated 
on a volume-limited respirator (Servo 900D, Siemens- 
Elema, Solna, Sweden) via a tracheostomy. All animals 
received humane care in compliance with the "Principles 
of Laboratory Animal Care" formulated by the National 
Society for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Na- 
tional Academy of Sciences, published by the National 
Institutes of Health (NIH publication No. 86-23, revised 
1985). The surgical preparation for CPB, including vessel 
cannulation for blood sampling and monitoring, is similar 
to that described previously. 15
Measurements  
Acid-base and blood gas analyses. Systemic arterial and 
venous blood gas, electrolyte, and hemoglobin measure- 
ments were made every 15 minutes during CPB (Blood 
Gas System 288, CIBA-Corning, Medfield, Mass.). Body 
oxygen delivery and uptake were calculated by the follow- 
ing equations: 
Oxygen delivery ([)02, ml/min/kg) = 
F × Cao~oodyweight (kg) 
Oxygen utilization (Vo2, ml/min/kg) = 
F × (Cao2-Cvo2)/bodyweight(kg) 
where F is pump flow (milliliters per minute), Cao 2 is 
oxygen content in arterial blood, ,and Cvo2 is oxygen 
content in systemic venous blood. 
Hemodynamics. Cardiac output was determined by du- 
plicate injections of 1 ml of 4°C saline solution into a 
central venous catheter. Cardiac index (CI), systemic 
vascular resistance index (SVRI), and left ventricular 
stroke work index (LVSWI) were calculated with the 
following equations: 
CI (ml/min/kg) = CO/body weight (kg) 
SVRI (mmHg • rain • L-~ • kg) = 
(MAP - CVP) (ram Hg) • CO - 1 (ml/min) • BW (kg) 
LVSWI (g • m/kg) = (MAP - LAP) × CO (ml/min) 
x 0.0136/(HR × body weight [kg]) 
where MAP is mean aortic pressure, LAP is mean left 
atrial pressure, CVP is central venous pressure, HR is 
heart rate, and CO is cardiac output measured by ther- 
modilution method or CPB pump flow rate in milliliters 
per minute. 
Myocardialperformance. LV pressure and conductance 
catheter signals were amplified and digitalized to inscribe 
left ventricular pressure-volume loops. After the proce- 
dure for correction of parallel conductance, a series of 
pressure-volume loops under variable loading condi- 
tions was generated by rapid transient occlusion of the 
inferior vena cava during a 7-second period of apnea, at 
a control condition, and 30 minutes after discontinua- 
tion of CPB. 16 
The end-systolic pressure volume relationship (ESPVR) 
was analyzed by an interactive videographics data analysis 
computer program (Spectrum, Bowman Gray School of 
Medicine, Winston-Salem, N.C.) on an 386/33 MHz IBM 
computer (IBM, Armonk, N.Y.), and LV performance was 
described as the slope of linear regression (end-systolic 
elastance), as described previously. 17 Postbypass LV contrac- 
tility was assessed by percent recovery of prebypass control 
value (percent end-systolic elastance). 
LV performance before and after CPB was also evalu- 
ated by infusing blood from the CPB circuit at 5 ml/min/kg 
over a 3-minute period while recording CO, MAP, and 
LAP to inscribe Starling function curves. 
Myocardial conjugated diene and creatine kinase produc- 
tion. For blood biochemical assessments, he aorta was 
clamped temporarily (1 to 2 minutes) while the proximal 
aorta was perfused with blood by way of a calibrated pump 
to keep the aortic root pressure 50 to 60 mm Hg. Blood 
samples were withdrawn from the proximal aorta and the 
coronary effluent (coronary sinus blood) and analyzed for 
conjugated dienes (CDs) and creatine kinase (CK) during 
control (normoxemia), hypoxemia, and 5, 30, and 60 
minutes of the reoxygenation period. They were centri- 
fuged immediately for 5 minutes at 1000g, and plasma was 
then stored in liquid nitrogen and hydroxyconjugated 
diene levels determined as described by Lesnefsky and 
coworkers. 18 The plasma concentration of CK was mea- 
sured by the method of Oliver. 19 Myocardial production 
of CDs and CK was calculated by the following equation: 
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Fig. 1. Effects of hypoxemia-reoxygenation and administration of deferoxamine on systemic vascular 
resistance index (SVRI). No Rx (closed circles): reoxygenation on CPB without treatment (n = 9); 
deferoxamine (open squares): piglets with deferoxamine administration 10 minutes before reoxygenation 
(arrow). *p < 0.05 versus no treatment. 
Myocardial production = (Ccs-Ca) × CBF/(100 g)heart 
weight where Ccs and Ca are concentration i coronary 
sinus and arterial plasma blood sample (assuming plasma 
and red blood cell volumes are equal) and CBF (coronary 
blood flow, milliliters per minute) is a flow rate via a 
calibrated pump into the proximal aorta during temporary 
aortic clamping. 
Antioxidant reserve capacity. The myocardial endoge- 
nous antioxidant state was assessed by determining in 
vitro lipid peroxidation i LV subendocardial muscle after 
each experiment was completed by the method of Godin 
as described previously. 2°
Experimental protocols 
Controls. Five normoxemic, ontrol piglets were anes- 
thetized, instrumented, and observed over a 5-hour period 
to provide baseline functional and biochemical data with- 
out CPB. Five other piglets underwent 2 hours of CPB 
without hypoxemia (perfusion flow rate about 100 ml/min/ 
kg) followed by 30 minutes of post-CPB observation while 
ventilated with 100% oxygen. This post-CPB oxygen man- 
agement protocol was followed in all experimental stud- 
ies. 
Experimental In 16 piglets CPB was started at nor- 
moxemia (oxygen tension [P%] about 100 mm Hg). 
Mean aortic pressure was kept at 50 to 60 mm Hg by 
adjusting perfusion flow rate between 90 and 100 
ml/min/kg. After 5 minutes of normoxemic perfusion, 
hypoxemia was produced on CPB by lowering inspired 
oxygen fraction (Fio2) in the oxygenator for 60 minutes 
by adding N 2 to the gas mixture to reduce Po a to about 
25 mm Hg. Packed red blood cells were added to raise 
hematocrit level to 45% after hypoxemia was induced, 
and perfusion flow rate was increased to about 130 
ml/min/kg. This hypoxemic interval was then followed 
by 60 minutes of reoxygenation while receiving CPB at 
Po2 about 400 mm Hg. 
No TREATMENT. Nine piglets underwent aforemen- 
tioned protocol without treatment. 
DEFEROXAM1NE TREATMENT. In seven piglets a bolus 
injection of 5 mg/kg was added to the CPB circuit 10 
minutes before reoxygenation, at which time an intrave- 
nous infusion was started and continued until the end of 
CPB to provide an additional 45 mg/kg dose (total dose 50 
mg/kg). This dose was selected because in two pilot 
experiments a total deferoxamine dose of 100 mg/kg 
resulted in severe vasoconstriction a d precluded iscon- 
tinuation of CPB (see "Results"). 
Final functional assessments were performed and spec- 
imens for biochemical nalyses were obtained 30 minutes 
after CPB was discontinued. 
Statistics. Data were analyzed with the use of the 
StatView V2.0 program (Abacus Concepts Inc., Berke- 
ley, Calif.) on a Macintosh Ilci computer (Apple, Inc., 
Cupertino, Calif.). Analysis of variance was used for 
intergroup comparison, and the paired Student t test 
was used for comparison of variables within experimen- 
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Fig. 2. Postbypass LV contractility. LV end-systolic elastance (Ees) after discontinuation of CPB, 
expressed as percentage of individual prehypoxemic values. CPB, Piglets underwent hyperoxic bypass 
without hypoxemia; no Rx, piglets untreated; deferoxamine, piglets treated with deferoxamine. *p < 0.05 
versus CPB; ?p < 0.05 versus no treatment. 
tal groups. The relationship between functional impair- 
ment (percent elastance) and lipid peroxidation (CDs) 
was tested by linear regression analysis. Differences 
were considered significant at the probability level of 
p < 0.05. Group data were expressed as mean plus or 
minus standard error of the mean. 
Results 
Hemodynamics. Systemic (CPB) flow averaged 
100 ml/min/kg at about 60 mm Hg in control studies 
without hypoxemia to provide body oxygen delivery 
(Do2) of 13 _+ 0.3 ml/min/kg. A comparable body 
Do2 was also achieved uring hypoxemia by increas- 
ing CPB flow 30% and raising hematocrit level to 
45%; no metabolic acidosis occurred because pH 
remained about 7.4 (Table). 
Hypoxemia during CPB caused comparable sys- 
temic vasodilation in untreated and deferoxamine- 
treated groups as SVRI fell to 61% +_ 5% and 
63% +- 7%, respectively (Fig. 1). Deferoxamine 
raised SVRI progressively during reoxygenation, 
and resistance remained increased uring the post- 
CPB interval; SVRI returned to control levels in 
untreated piglets (Fig. 1). The vasoconstrictive effect 
of deferoxamine was amplified in two pilot experi- 
ments in which a total 100 mg/kg hour dose raised 
SVRI 180% above pre-CPB values and precluded 
discontinuation of CPB. 
LV performance. LV elastance r turned to 102% + 
9% of control values after CPB without hypoxemia 
(Fig. 2). Conversely, reoxygenation without treat- 
ment was associated with only 39% _+ 7% recovery 
of end-systolic elastance (p < 0.05 versus CPB). 
Deferoxamine treatment restored LV contractility 
to 95% + 11% of pre-CPB levels (p < 0.05 versus 
no treatment) (Fig. 2). A parallel depression of 
myocardial performance occurred when func- 
tional reserve was tested by volume infusion (Star- 
ling curve analysis), because untreated piglets 
recovered only 38% _+ 9% of LVSWI at LAP 12 
mm Hg, whereas LVSWI recovered 84% _+ 14% 
at comparable LAP in piglets treated with de- 
feroxamine (Fig. 3). 
Myocardial CD production. CD production was 
unchanged in piglets placed on CPB without hypox- 
emia (Fig. 4). Reoxygenation without treatment 
raised CD production 210% after 60 minutes of 
reoxygenation (3.46 +_ 0~73 absorbance 233 rim/rain/ 
100 g, p < 0.05 versus CPB control), whereas 
negligible CD production occurred after deferoxam- 
ine treatment (CD production 0.7 +_ 0.2, p < 0.05 
versus no treatment). 
CK release. Myocardial CK release was negligi- 
ble in piglets placed on CPB without hypoxemia 
(Fig. 5). Reoxygenation without reatment caused a 
progressive release of CK after reoxygenation and 
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Fig. 3. LV performance by volume infusion before hypoxemia (control: open circles), after eoxygenation 
with deferoxamine (deferoxamine: open squares), and without reatment (no Rx: closed circles). LAP, Left 
atrial pressure, LVSWI, left ventricular stroke work index. 
reached 330% above pre~ypoxemic values 60 min- 
utes after reoxygenation ~(&5 - 1.5 U/rain/100 gm, 
p < 0.05 versus CPB contfol). In contrast, no CK 
production occurred in piglets receiving deferoxam- 
ine treatment. 
Antioxidant reserve capacity, Reoxygenation ( o 
treatment) reduced antioxidafit ieserve capacity as 
more malondialdehyde was prodUced in myocardial 
homogenates incubated with: th~ oxidant -butylhy- 
droperoxide. Conversely, antioxidant reserve capac- 
ity remained normal when deferoxamine was admin- 
istered before reoxygenation (Fig. 6). 
Discuss ion 
This study confirms an fmportant r01e of iron- 
catalyzed oxidants in the pathogenesis of surgical 
reoxygenation injury of Subj~ects atthe onset of CPB 
by showing that the iron chelator, deferoxamine, 
reduces lipid peroxidation (CD production), mem- 
brane disruption (CK leakage), depletion of endog- 
enous antioxidants, and depressed myocardial per- 
formance after reoxygenation. 
The in vivo model of hypoxemia on CPB is a 
reproddcible expeiimental setting that avoids hemo- 
dynamic deterioration and metabolic acidosis and 
ensures optimal systemic and myocardial oxygen 
supply. The use of increased perfusion flow rate and 
hematocrit level during hypoxemia pro, vides ' compa- 
rable oxygen delivery to that occurring during nor- 
moxemia nd avoided metabolic acidosis (Table). 
This compensated state has some relevance to 
chronic cyanosis, in which metabolic adaptations 
allow normal aerobic metabolism toprevailY Func- 
tional and biochemical myocardial damage followed 
reoxygen~tion despite compensated hypoxemia. 
These observations are consistent with recent clini- 
cal findings of reoxygenation-induced lipi peroxi- 
dation and myocardial dysfunction i  patients with 
hypoxemia plhced on CPB or extracorporeal mem- 
brane oxygenation. 2' 4
Song several oxygen radicals, hydroxyl radical 
(.OH) is the most oxic and causes lipid peroxidation 
and protein thi01 oxidation, 7's which results in myo- 
cardial and endothelial cell injury on reoxygenation/ 
reperfusion.22, 23 Iron may play a central role in 
oxygen radical generation and the subsequent chain 
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Fig. 4. Myocardial CD production during hypoxemia-reoxygenation on CPB. CPB, Piglets underwent 
hyperoxic bypass without hypoxemia, no Rx, piglets untreated; eferoxamine, piglets treated with deferox- 
amine. *p < 0.05 versus CPB; tp < 0,05 versus no treatment. 
reaction of !ipid peroxidation leading to membrane 
disruptio n. Ferric iron (Fe 3+) catalyzes the Haber- 
Weiss reaction, whereby 02- and H20 2 lead to the 
highly reactive -OH radical. 6Another potential det- 
rimental role of iron ls to catalyze the propagation 
of lipid perox~dation after its initiation by ,OH, 6 
because lipid hydroperoxides formed in the course 
of -OH-initiated lipid peroxidation can react with 
iron compounds to give alkoxyl and peroxyl radicals 
that further oxidize other fatty acids. 6An alternate 
mechanism for generating .OH may be the L-argi- 
nine-nitric oxide pathway, in which .NO interacts 
with O a- to produce peroxynitrite (OON()-), which 
further decays to .OH. 24 A recent report documents 
that .NO mediates iron release from ferritin, 25 and 
mobilized ferrous iron is thereby available to react with 
H20 2, suggesting the additional cytotoxic role of "NO 
is in the iron-catalyzed Haber-Weiss reaction. 02- can 
also directly release "iron" from ferritin by reducing 
tl~e metal to the Fe 2÷ state, thereby making it available 
for the aforementioned reactions. 26-28 
Deferoxamine is a chelating agent with a high 
affinity for ferric iron (Fe3+). It enters cells readily, 11 
prevents iron-catalyzed formation of .OH from 02-, 29 
and iron-dependent lipid peroxidation. 22Its cardiopr 0- 
tective ffect has been documented in experimental 9-12 
and clinical ~°' 31 ischemia/reperfusion injury studies by 
showing reduced free radical production by electron 
paramagnetic resonance spectroscopy, 11' 32 decregsed 
oxygen-mediated lipid peroxidation, 13'29 and im- 
proved myocardial function 9-12 with avoidance of high- 
energy phosphate depletion. 1°'13 Deferoxamine is 
known to scavenge 02 -33 and .OH directly, 34 but its 
primary benefit appears related to its ability to bind 
iron, because some reports showed diminished effi- 
ciency in iron-loaded models. 9;35 
Our observatidns in the hypoxemic/reoxygenation 
model showing that deferoxamine reduced lipid 
peroxidation, decreased enzyme leak, and improved 
recovery strengthen the concept hat iron-mediated 
oxidants play a role in the pathogenesis of reoxygen- 
ation injury. Our dosage and administration proto- 
col were derived from a previous in vivo Study for 
regional ischemia 9 and was modified to account for 
the expanded volume introduced by CPB pump 
circuitry. The half-life of deferoxamine is short 
(about 5 minutes), 13 and thus the combination of a 
continuous intravenous infusion and a bolus injec- 
tion seemed essential to attain therapeutic concen- 
tration. Progressive release of CK and CDs occurred 
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Fig. 5. Myocardial CK production during hypoxemia-reoxygenation on CPB. CPB, Piglets underwent 
hyperoxic bypass without hypoxemia, no Rx, piglets untreated; eferoxamine, piglets treated with deferox- 
amine. *p < 0.05 versus CPB; ?p < 0.05 versus no treatment. 
throughout 60 minutes of reoxygenation i  un- 
treated piglets, whereas udden increases in myocar- 
dial and coronary sinus CD levels were reported in 
ischemia/reperfusion settings. 18' 36 This observation 
may indicate that ongoing oxidative damage may 
occur during reoxygenation a d that an iron chela- 
tor should be administered for an extended interval 
after reoxygenation. 
We observed that deferoxamine produced sig- 
nificant increase in SVRI in immature piglets, 
especially when a high dose was used (total 100 
mg/kg), and this has not been reported previously. 
A similar vascular response occurred when L- 
arginine analogs (that block nitric oxide synthase) 
were added to the extracorporeal circuit prime in 
an effort to limit reoxygenation i jury by interfer- 
ing with the L-arginine-.NO pathway. 5 These sys- 
temic effects of deferoxamine, like those of L- 
arginine analogs, would not be detected in the 
isolated heart preparation and may reduce the 
physiologic effects of .NO inhibition for modulat- 
ing vascular tone and result in ischemia of organs 
that lack the vasoregulatory capacity of the myo- 
cardium (i.e., pancreas). 37 Recent reports suggest 
nitric oxide synthase, which contains iron, may be 
inhibited by other compounds that bind iron, 38 so 
that deferoxamine might cause vasoconstriction 
by inhibiting endothelium-derived relaxing factor 
production and may also thereby be cardioprotec- 
tive by limiting NO production and preventing 
formation of OONO-  that decomposes homolyti- 
cally to produce .OH. 24 
Implications. The concept that iron-mediated ox- 
idant damage occurs during reoxygenation of sub- 
jects with cyanosis has potential therapeutic impli- 
cations, because deferoxamine has been used to 
treat iron and aluminum poisoning TM and a compa- 
rable dose to that used in this study has been shown 
to be safe in cardiac operations. 3°One prior report, 
however, noted acute toxicity after intravenous in- 
fusion of deferoxamine. 39 Clearly, the therapeutic 
dosage of deferoxamine must be defined by studying 
both systemic and myocardial effects before this 
drug could be recommended for clinical use. 
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Fig. 6. Antioxidant reserve capacity. Vulnerability of reoxygenated myocardium to subsequent oxidant 
stress is determined by exposing tissue to 0 to 4 mmol/L t-butylhydroperoxide (t-BHP) for 30 minutes at 
37 ° C with subsequent measurement of TBA-reactive substances. MDA standard curve is run simulta- 
neously, as lipid peroxidation is expressed as MDA nmol/g protein. Control, Piglets without CPB; no Rx, 
piglets untreated; eferoxamine, piglets treated with deferoxamine. *p < 0.05 versus CPB, ?p < 0.05 versus 
no treatment. MDA, Malondialdehyde. 
Table. Physiologic profile during hypoxemia on CPB 
Hypoxemia 
Prehypoxemia No Rx Deferoxamine 
pH 7.48 -+ 0.02 7.41 +- 0.01 7.43 -- 0.02 
Pao2 (mm Hg) 126.5 _+ 14 24.0 _+ 0.67* 23.2 ± 0.87* 
Paco 2 (mm Hg) 25.1 _+ 2.0 29.3 ± 1.5 29.9 +_ 1.2 
Hct (%) 31.5 ± 1.5 45.5 +- 1.4" 44.5 _+ 2.4* 
PFI (ml/min/kg) 109 +_ 6 129.5 + 5.9* 132.2 _+ 4.3* 
Do 2 (ml/min/kg) 13.0 _+ 0.34 13.4 ± 0.89 13.9 ± 1.09 
Vo 2 (ml/min/kg) 7.4 _+ 0.9 8.5 +_ 0.5 7.9 ± 0.9 
No Rx, No treatment; Hct, hematocrit on CPB; PFI, perfusion flow rate on CPB (ml/min/kg); Do2, oxygen delivery (ml/min/kg); Vo2, oxygen consumption 
(ml/min/kg). 
*p < 0.05 versus prebypoxemic values (paired t test). 
We conclude that deferoxamine administered in- 
travenously before and during reoxygenation, cou- 
pled with adding a bolus injection to the extracor- 
poreal circuit, reduces oxygen-mediated myocardial 
damage substantially by limiting lipid peroxidation, 
enzymatic damage, and depressed myocardial per- 
formance. These findings support an important role 
of iron-catalyzed oxidants in the pathogenesis of 
reoxygenation i jury. However, the observed pro- 
duction of systemic vasoconstriction i  a dose-de- 
pendent fashion might nullify its cardioprotective 
action. Additional studies are needed to define the 
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safe therapeutic dosage before consideration of use 
of this drug during surgical correction of congenital 
defect causing cyanosis in infants. 
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